Feed / IDYA

IDEAYA Biosciences, Inc.

IDYA

Healthcare · 39.71 +1.5% today

Partial group confirmationMarket checked 21 Aug, 15:55 GMT-4

Jodie situation report

IDEAYA Biosciences, Inc.'s move is being confirmed by its market group.

IDYA accounts for 21.9% of the group's measured movement across 3.9 effective names. raw member direction is mixed; 3 of 5 session-normalized paths align to the downside. Capital-flow agreement is 29%, so confirmation is not yet clean. No verified headline preceded the measured group move.

MOVE ANATOMY

Is this move genuinely shared?

Session-normalized 5m paths
Role in the moveCounter-move#3 of 5 by movement share
Group movement share21.9%Absolute path energy—not portfolio weight
Relative path+1.90%counter
Effective breadth3.9 / 5balanced
Relative alignment3/5downside path · 2 counter-moving
Capital-flow agreement29%not yet clean
SEQUENCE READ

IDYA was the first measured mover. IDYA crossed its material path threshold at 09:30 ET. CELC, RVMD, BCRX followed.

EVIDENCE COVERAGE

5 of 5 members in Clinical Biotechnology are active. 0 of 7 disclosed connections are confirming.

What would change this read
  • At least 4 of 5 members remain active in the next snapshot.
  • Capital-flow agreement rises above 55%.
  • A filing-linked outsider such as ABCL begins moving with the group.

Invalidation: The live read weakens if participation falls to 1 of 5 members or fewer.

Watch this read

Who this business touches

The relationships behind IDYA

Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.

Depends on

GILDGilead Sciences, Inc.partnerFeb 17, 2026 ▾

“We have also partnered with leading pharmaceutical companies, including GSK, Pfizer and Gilead to support clinical development activities for our pipeline programs.”

PFEPfizer, Inc.partnerFeb 17, 2026 ▾

“We have also partnered with leading pharmaceutical companies, including GSK, Pfizer and Gilead to support clinical development activities for our pipeline programs.”

Depended on by

TNGXTango Therapeutics, Inc.competitorMar 5, 2026 ▾

“Additionally, there are other indirect competitors running clinical trials in the PRMT5 inhibition space, including IDEAYA Biosciences, BeOne, Insilico Medicine and Servier Pharmaceuticals, which each have clinical MAT2A inhibitor programs.”

Filing peers

No filing peers are available for this name yet.

Open the three relationships above to see Jodie’s filing proof. Pro unlocks 4 more links, every receipt, and alerts when connected names begin moving. Unlock the full network →

What is moving around it

Live connections

IDYA is currently a Leader in the organic co-movement group Clinical Biotechnology. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 3 filing-linked names are in the relationship map; none is currently confirmed as moving with the group.